Results 71 to 80 of about 109,968 (264)

Chimeric antigen receptor T-cell therapy [PDF]

Indian Journal of Medical and Paediatric Oncology, 2020
Azgar Abdul Rasheed, Venkata Pradeep Babu Koyyala   +1 more
openaire   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report

Journal of Medical Case Reports
Background Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton’s tyrosine kinase inhibitors proving effective but not curative.
G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero   +7 more
doaj   +1 more source

Chimeric antigen receptor T cell therapies for multiple myeloma

Journal of Hematology & Oncology, 2019
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies.
Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan, Lijuan Chen   +4 more
doaj   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

Chimeric antigen receptor T cell therapy for multiple myeloma

Inflammation and Regeneration, 2019
Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma.
Kana Hasegawa, Naoki Hosen
doaj   +1 more source

Halofuginone is a Molecular Glue Degrader of Integrin β4

Advanced Science, EarlyView.
Integrin β4 overexpression is linked to aggressive tumors and poor prognosis, but targeted therapies are lacking. We identified halofuginone (HF) as a molecular glue degrader that promotes integrin β4 degradation via the CRL4BWDR18 E3 ligase. HF suppresses tumor progression in vitro and in vivo, offering a new strategy for targeting oncogenic ...
Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan   +8 more
wiley   +1 more source

Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9

Protein & Cell, 2017
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology.
Jiangtao Ren, Yangbing Zhao
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Gut Lactate Boosts Ruminococcus via Histone Lactylation to Mediate Time‐Restricted Feeding Protection in Crohn's Disease

Advanced Science, EarlyView.
TRF enriches Ruminococcus, a bacterial genus producing SCFAs, and activates the epithelial HIF‐1α signaling pathway. This mechanism protects the colonic mucosa from inflammatory insults in colitis models. Mechanistically, gut lactate production during starvation and refeeding mediates H4K12la, which increases SLC9A3 expression and creates an acidic gut
Linwen Huang, Huishi Tan, Senhui Weng, Yuntao Liu, Lingxu Song, Shaoyu Cheng, Zelong Lin, Jiawei Chen, Fei Tan, Jun Wang, Jinke Huang, Linkun Cai, Jiwei Chai, Cailing Zhong, Yanqiang Shi, Wendi Zhang, Haiyan Zhang, Chongyang Huang   +17 more
wiley   +1 more source